CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Clinical Data, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Clinical Data, Inc.
One Gateway Center
Suite 702
Phone: (617) 527-9933p:617 527-9933 Newton, MA  02458  United States Ticker: CLDACLDA
This company ceased filing statements with the SEC on 4/25/2011.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Clinical Data, Inc. is focused on the development and commercialization of therapeutics, with two compounds in the areas of central nervous system and cardiovascular disorders. The Company’s late-stage drug candidate is vilazodone, a dual-acting selective and potent serotonin reuptake inhibitor and serotonin receptor 1A (5-HT1A) partial agonist for the treatment of major depressive disorder (MDD). The Company’s second late-stage drug candidate is apadenoson, trademarked Stedivaze, a selective adenosine receptor 2A (AR2A) agonist and coronary vasodilator in Phase III of clinical development for use in nuclear Single Photo Emission Computed Topography (SPECT) myocardial perfusion imaging. The Company also provides the FAMILION family of genetic tests for inherited cardiac syndromes, including cardiac channelopathies and cardiomyopathies. On September 30, 2009, the Company purchased all the assets of Epix Pharmaceuticals, Inc. (Epix).
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 IRA CQ
Score		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating		 Morningstar
Rating
-Yes-------

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20103/31/2010YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Randal J.Kirk 57 12/1/2004 1/1/2002
President, Chief Executive Officer, Director Andrew J.Fromkin 44 5/12/2006 5/12/2006
Chief Financial Officer, Executive Vice President C. EvanBallantyne 50 1/1/2009 8/7/2006
8 additional Officers and Directors records available in full report.

Business Names
Business Name
API Acquisition Sub, Inc.
Avalon Pharmaceuticals, Inc.
CLDA
PGxHealth Holding, Inc.
PGxHealth, LLC

General Information
Number of Employees: 160 (As of 3/31/2010)
Outstanding Shares: 30,954,909 (As of 2/8/2011)
Shareholders: 467
Stock Exchange: NASD
Federal Tax Id: 042573920
Email Address: info@novitronintl.com


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, October 24, 2019